

Paul M Barr

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7053054/paul-m-barr-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|-------------------------|----------------|-----------------|
| 207 papers | 8,099 citations | 38 h-index | 88 g-index |
| 226 ext. papers | 9,909 ext. citations | 4.6 avg, IF | 5.46 L-index |

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 207 | Zilovetamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers 2022 , 1, | | 4 |
| 206 | Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.. <i>Blood</i> , 2022 , | 2.2 | 10 |
| 205 | Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.. <i>Leukemia and Lymphoma</i> , 2022 , 1-9 | 1.9 | |
| 204 | Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.. <i>Leukemia and Lymphoma</i> , 2022 , 1-5 | 1.9 | 0 |
| 203 | Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021 , 106, 284-287 | 6.6 | 1 |
| 202 | Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021 , 138, 2640-2640 | 2.2 | |
| 201 | Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7501-7501 | 2.2 | 9 |
| 200 | Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7523-7523 | 2.2 | 9 |
| 199 | Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2257-2265 | 2.2 | 6 |
| 198 | Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. <i>Leukemia</i> , 2021 , 35, 1788-1791 | 10.7 | 18 |
| 197 | Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K inhibitor therapy. <i>Blood</i> , 2021 , 137, 2817-2826 | 2.2 | 19 |
| 196 | Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 598-605 | 1.9 | 1 |
| 195 | COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021 , 138, 1768-1773 | 2.2 | 12 |
| 194 | Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3278-3282 | 1.9 | 1 |
| 193 | Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2021 , 19 Suppl 11, 17-19 | 0.6 | |
| 192 | Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). <i>Leukemia and Lymphoma</i> , 2020 , 61, 1636-1644 | 1.9 | 1 |
| 191 | Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1627-1635 | 1.9 | 4 |

| | | | |
|-----|--|------|-----|
| 190 | Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020 , 26, 3589-3596 | 12.9 | 43 |
| 189 | A cross-trial comparison of single-agent ibrutinib chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020 , 105, e164-e168 | 6.6 | 4 |
| 188 | Early Progression of Follicular Lymphoma: Biology and Treatment. <i>Hematology/Oncology Clinics of North America</i> , 2020 , 34, 757-769 | 3.1 | 2 |
| 187 | Initial treatment of B-cell prolymphocytic leukemia with ibrutinib. <i>American Journal of Hematology</i> , 2020 , 95, E108-E110 | 7.1 | 2 |
| 186 | Arrhythmia Burden in Patients with Indolent Lymphoma. <i>Blood</i> , 2020 , 136, 6-7 | 2.2 | 0 |
| 185 | Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE). <i>Blood</i> , 2020 , 136, 19-22 | 2.2 | |
| 184 | A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 41-42 | 2.2 | 6 |
| 183 | Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. <i>Blood</i> , 2020 , 136, 39-41 | 2.2 | 8 |
| 182 | Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells. <i>Blood</i> , 2020 , 136, 45-45 | 2.2 | 3 |
| 181 | Real-world practice patterns in follicular lymphoma (FL) care at community oncology centers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 231-231 | 2.2 | |
| 180 | Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8038-8038 | 2.2 | 0 |
| 179 | Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8035-8035 | 2.2 | |
| 178 | Complete recovery of late onset progressive multifocal leukoencephalopathy related to treatment with chemoimmunotherapy: A case report. <i>Leukemia Research</i> , 2020 , 90, 106309 | 2.7 | 2 |
| 177 | The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, 918-923 | 4.5 | 10 |
| 176 | Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. <i>American Journal of Hematology</i> , 2020 , 95, E16-E18 | 7.1 | 2 |
| 175 | Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2020 , 188, e33-e36 | 4.5 | 0 |
| 174 | Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020 , 136, 1134-1143 | 2.2 | 132 |
| 173 | Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3003-3011 | 2.2 | 33 |

| | | | |
|-----|--|------|-----|
| 172 | Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020 , 9, 8468-8479 | 4.8 | 8 |
| 171 | The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020 , 10, 1-5 | 2.6 | 1 |
| 170 | Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020 , 34, 787-798 | 10.7 | 185 |
| 169 | How I treat early-relapsing follicular lymphoma. <i>Blood</i> , 2019 , 133, 1540-1547 | 2.2 | 26 |
| 168 | Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019 , 25, 4264-4270 | 12.9 | 37 |
| 167 | Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. <i>British Journal of Haematology</i> , 2019 , 186, 255-262 | 4.5 | 10 |
| 166 | Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019 , 133, 2031-2042 | 12.3 | 123 |
| 165 | Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. <i>Haematologica</i> , 2019 , 104, 2258-2264 | 6.6 | 16 |
| 164 | Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. <i>British Journal of Haematology</i> , 2019 , 186, 175-180 | 4.5 | 5 |
| 163 | A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. <i>Investigational New Drugs</i> , 2019 , 37, 297-306 | 4.3 | 35 |
| 162 | Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3081-3089 | 2.2 | 63 |
| 161 | Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019 , 134, 1238-1246 | 2.2 | 50 |
| 160 | Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3569-3572 | 1.9 | 4 |
| 159 | Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 715-722.e6 | 2 | 22 |
| 158 | Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019 , 24, e1236-e1250 | 5.7 | 20 |
| 157 | Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019 , 381, 432-443 | 59.2 | 322 |
| 156 | Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 1353-1363 | 7.1 | 152 |
| 155 | Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019 , 134, 35-35 | 2.2 | 30 |

| | | | |
|-----|--|-----|----|
| 154 | Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. <i>Blood</i> , 2019 , 134, 797-797 | 2.2 | 2 |
| 153 | A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 2834-2834 | 2.2 | 1 |
| 152 | A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019 , 134, 360-360 | 2.2 | 8 |
| 151 | Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019 , 134, 502-502 | 2.2 | 4 |
| 150 | PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019 , 134, 349-349 | 2.2 | 11 |
| 149 | Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019 , 134, 1756-1756 | 2.2 | 1 |
| 148 | Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice. <i>Blood</i> , 2019 , 134, 682-682 | 2.2 | 1 |
| 147 | Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019 , 134, 33-33 | 2.2 | 22 |
| 146 | Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7510-7510 | 2.2 | 1 |
| 145 | Cognitive function in chronic lymphocytic leukemia (CLL): Examining effects of disease, treatment, and inflammation.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11584-11584 | 2.2 | 1 |
| 144 | Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7547-7547 | 2.2 | |
| 143 | High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e19058-e19058 | 2.2 | |
| 142 | Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2019 , 134, 3054-3054 | 2.2 | 1 |
| 141 | Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019 , 134, 3048-3048 | 2.2 | |
| 140 | Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019 , 186, 184-188 | 4.5 | 5 |
| 139 | Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019 , 94, 554-562 | 7.1 | 20 |
| 138 | Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019 , 3, 1799-1807 | 7.8 | 61 |
| 137 | A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019 , 3, 1568-1573 | 7.8 | 18 |

| | | | |
|-----|---|------|-----|
| 136 | Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019 , 3, 3132-3135 | 7.8 | 10 |
| 135 | Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <i>British Journal of Haematology</i> , 2019 , 185, 961-966 | 4.5 | 6 |
| 134 | Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 41-47 | 2 | 14 |
| 133 | Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018 , 103, 874-879 | 6.6 | 219 |
| 132 | R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. <i>Lancet Haematology</i> , 2018 , 5, e102-e108 | 14.6 | 15 |
| 131 | Phase 1 study of the PI3K inhibitor INCB040093 + JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. <i>Blood</i> , 2018 , 132, 293-306 | 2.2 | 32 |
| 130 | Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2018 , 59, 625-632 | 1.9 | 44 |
| 129 | Management of melanoma in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2018 , 71, 43-46 | 2.7 | 11 |
| 128 | Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2018 , 103, e249-e251 | 6.6 | 4 |
| 127 | Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018 , 93, 1394-1401 | 7.1 | 37 |
| 126 | Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. <i>Cancer Immunology Research</i> , 2018 , 6, 1150-1160 | 12.5 | 40 |
| 125 | Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018 , 93, 1402-1410 | 7.1 | 19 |
| 124 | Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018 , 103, 1502-1510 | 6.6 | 82 |
| 123 | Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018 , 103, 1511-1517 | 6.6 | 91 |
| 122 | Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018 , 132, 5565-5565 | 2.2 | 3 |
| 121 | Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial. <i>Blood</i> , 2018 , 132, 1691-1691 | 2.2 | 4 |
| 120 | Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018 , 132, 929-929 | 2.2 | 5 |
| 119 | Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018 , 132, 3142-3142 | 2.2 | 2 |

| | | | |
|-----|--|------|-----|
| 118 | Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018 , 132, 6-6 | 2.2 | 13 |
| 117 | Acalabrutinib combined with PI3K inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7518-7518 | 2.2 | 6 |
| 116 | A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7530-7530 | 2.2 | 5 |
| 115 | Correlates of anxiety and depression in chronic lymphocytic leukemia (CLL) survivors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 153-153 | 2.2 | 1 |
| 114 | Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6577-6577 | 2.2 | |
| 113 | Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7521-7521 ² | 2.2 | 2 |
| 112 | Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018 , 132, 1593-1593 | 2.2 | |
| 111 | Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. <i>Blood</i> , 2018 , 132, 4759-4759 | 2.2 | 0 |
| 110 | Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 65-75 | 21.7 | 228 |
| 109 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018 , 379, 2517-2528 | 59.2 | 455 |
| 108 | Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 781-787 | 2 | 4 |
| 107 | Pitfalls of Combining Novel Agents in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 35 | 5.4 | 0 |
| 106 | Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 648-657.e15 | 2 | 45 |
| 105 | Recommendations for Clinical Trial Development in Follicular Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017 , 109, | 9.7 | 16 |
| 104 | Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 145-151 | 2 | 6 |
| 103 | Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017 , 178, 286-291 | 4.5 | 47 |
| 102 | Efficacy in the margins of NHL with ibrutinib. <i>Blood</i> , 2017 , 129, 2207-2208 | 2.2 | |
| 101 | Long-term safety experience with bendamustine for injection in a real-world setting. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 647-650 | 4.1 | 1 |

| | | |
|-----|--|--------|
| 100 | Treatment of chronic lymphocytic leukemia in older adults. <i>Journal of Geriatric Oncology</i> , 2017 , 8, 315-319 | 9 |
| 99 | Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017 , 129, 2612-2615 | 2.2 89 |
| 98 | Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017 , 129, 3037-3039 | 2.2 57 |
| 97 | Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve. <i>Lancet Haematology</i> , 2017 , 4, e152-e153 | 14.6 |
| 96 | RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017 , 176, 759-769 | 4.5 26 |
| 95 | Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 535-546 | 7.1 14 |
| 94 | Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 2017 , | 2 |
| 93 | Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7510-7510 | 2.2 11 |
| 92 | Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 535-546 | 7.1 16 |
| 91 | Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. <i>Oncotarget</i> , 2017 , 8, 79864-79875 | 3.3 10 |
| 90 | KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS7569-TPS7569 | 2.2 |
| 89 | Central line-associated complications during treatment with DA-R-EPOCH therapy for NHL.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7543-7543 | 2.2 1 |
| 88 | Enrollment of high-risk patients with diffuse large B-cell lymphoma in clinical trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6536-6536 | 2.2 |
| 87 | CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS7577-TPS7577 | 2.2 |
| 86 | Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2016 , 101, e295-8 | 6.6 54 |
| 85 | Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016 , 128, 1458-64 | 2.2 57 |
| 84 | Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, e123-e127 | 2 5 |
| 83 | Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2016 , 57, 635-43 | 1.9 19 |

| | | | |
|----|--|-----|-----|
| 82 | Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016 , 128, 2041-2041 | 2.2 | 3 |
| 81 | 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. <i>Blood</i> , 2016 , 128, 2042-2042 | 2.2 | 6 |
| 80 | Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 234-234 | 2.2 | 32 |
| 79 | High Risk of Infections in Chronic Lymphocytic Leukemia Patients Treated with B-Cell Receptor Inhibitors. <i>Blood</i> , 2016 , 128, 3203-3203 | 2.2 | 2 |
| 78 | Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016 , 128, 3222-3222 | 2.2 | 16 |
| 77 | A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , 2016 , 128, 3705-3705 | 2.2 | 22 |
| 76 | Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016 , 128, 4383-4383 | 2.2 | 6 |
| 75 | Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , 2016 , 128, 4400-4400 | 2.2 | 2 |
| 74 | Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016 , 128, 637-637 | 2.2 | 43 |
| 73 | Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7519-7519 | 2.2 | 10 |
| 72 | Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7520-7520 | 2.2 | 8 |
| 71 | A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS7576-TPS7576 | 2.2 | 1 |
| 70 | Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801. <i>Blood</i> , 2016 , 128, 614-614 | 2.2 | |
| 69 | Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting. <i>Blood</i> , 2016 , 128, 5591-5591 | 2.2 | |
| 68 | Deregulation of NF- κ B, ie, a useful PMBL marker. <i>Blood</i> , 2016 , 128, 2591-2592 | 2.2 | 3 |
| 67 | Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , 2016 , 128, 2199-2205 | 2.2 | 135 |
| 66 | Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 322-328.e2 | 2 | 5 |
| 65 | US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2020-7 | 2.2 | 184 |

| | | | |
|----|---|------|-----|
| 64 | Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. <i>Blood</i> , 2016 , 127, 2411-5 | 2.2 | 113 |
| 63 | Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016 , 128, 1112-20 | 2.2 | 119 |
| 62 | Postibrutinib outcomes in patients with mantle cell lymphoma. <i>Blood</i> , 2016 , 127, 1559-63 | 2.2 | 171 |
| 61 | Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. <i>Cancer Medicine</i> , 2016 , 5, 3059-3067 | 4.8 | 14 |
| 60 | Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2399-404 | 2.2 | 82 |
| 59 | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015 , 21, 922-6 | 50.5 | 707 |
| 58 | Recent advances in the development of Aurora kinases inhibitors in hematological malignancies. <i>Therapeutic Advances in Hematology</i> , 2015 , 6, 282-94 | 5.7 | 10 |
| 57 | The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 125, 2915-22 | 2.2 | 92 |
| 56 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 2425-37 | 59.2 | 950 |
| 55 | Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 508-11 | 1.9 | 2 |
| 54 | Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015 , 126, 2744-2744 | 2.2 | 8 |
| 53 | A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. <i>Blood</i> , 2015 , 126, 3931-3931 | 2.2 | 2 |
| 52 | Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2015 , 126, 518-518 | 2.2 | 4 |
| 51 | Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. <i>Blood</i> , 2015 , 126, 715-715 | 2.2 | 24 |
| 50 | Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. <i>Blood</i> , 2015 , 126, 719-719 | 2.2 | 9 |
| 49 | Interim analysis of a phase I study of INCB040093, a PI3K γ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8520-8520 | 2.2 | 5 |
| 48 | A phase 1 study of INCB040093, a PI3K γ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8558-8558 | 2.2 | 5 |
| 47 | A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8607-TPS8607 | 2.2 | 1 |

| | | | |
|----|---|------|------|
| 46 | Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 213-23 | 59.2 | 1154 |
| 45 | Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 323-6; quiz 326 | 7.3 | 16 |
| 44 | Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2014 , 124, 1259-65 | 2.2 | 29 |
| 43 | Infection in chronic lymphocytic leukemia: parsimony has its limits. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2683-4 | 1.9 | |
| 42 | Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2014 , 19, 367-83 | 3.7 | 3 |
| 41 | The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1219-20 | 1.9 | |
| 40 | Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. <i>Blood</i> , 2014 , 124, 1990-1990 | 2.2 | 9 |
| 39 | Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE™ Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014 , 124, 3331-3331 | 2.2 | 19 |
| 38 | Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival. <i>Blood</i> , 2014 , 124, 3984-3984 | 2.2 | 1 |
| 37 | Clinical Features, Treatment, and Survival of Secondary Central Nervous System Lymphoma. <i>Blood</i> , 2014 , 124, 5389-5389 | 2.2 | 4 |
| 36 | Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7059-7059 | 2.2 | 7 |
| 35 | U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8523-8523 | 2.2 | 3 |
| 34 | Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2014 , 124, 3999-3999 | 2.2 | |
| 33 | Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma. <i>Blood</i> , 2014 , 124, 1746-1746 | 2.2 | |
| 32 | Adult Burkitt Lymphoma and Leukemia 2014 , 171-194 | | |
| 31 | A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. <i>Annals of Oncology</i> , 2013 , 24, 3076-81 | 10.3 | 32 |
| 30 | Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia</i> , 2013 , 27, 1769-73 | 10.7 | 46 |
| 29 | Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 1630-1630 | 2.2 | 25 |

| | | | |
|----|--|------|----|
| 28 | Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study. <i>Blood</i> , 2013 , 122, 525-525 | 2.2 | 25 |
| 27 | Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study. <i>Blood</i> , 2013 , 122, 89-89 | 2.2 | |
| 26 | Novel agents in mantle cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 191-200 | 4.00 | 3 |
| 25 | Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. <i>Clinical Immunology</i> , 2012 , 142, 237-42 | 9 | 16 |
| 24 | Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2383-9 | 1.9 | 22 |
| 23 | Rare B Cell Lymphoproliferative Disorders 2012 , 617-626 | | |
| 22 | A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels. <i>Blood</i> , 2012 , 120, 1640-1640 | 2.2 | 1 |
| 21 | The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. <i>Blood</i> , 2012 , 120, 686-686 | 2.2 | 84 |
| 20 | Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 6515-6515 | 2.2 | 11 |
| 19 | Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8032-8032 | 2.2 | 7 |
| 18 | The incorporation of rituximab (R) and liposomal doxorubicin (LD) into CODOX-m/IVAC for untreated Burkitt lymphoma (BL): Final results of a prospective multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8080-8080 | 2.2 | |
| 17 | Fostamatinib Inhibits BCR Signaling, and Reduces Tumor Cell Activation and Proliferation in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012 , 120, 2882-2882 | 2.2 | |
| 16 | Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 970-8 | 4.7 | 38 |
| 15 | Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, e123-5 | 4.5 | 3 |
| 14 | Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. <i>Journal of Geriatric Oncology</i> , 2011 , 2, 215-221 | 3.6 | 5 |
| 13 | Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. <i>Leukemia Research</i> , 2011 , 35, e223-4 | 2.7 | 17 |
| 12 | Getting to the heart of the problem in treating diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1166-7 | 1.9 | |
| 11 | Pharmacology of Acute Lymphoblastic Leukemia Therapy 2011 , 127-144 | | |

| | | | |
|----|--|------|----|
| 10 | Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. <i>Cell Death and Differentiation</i> , 2010 , 17, 1381-91 | 12.7 | 49 |
| 9 | Non-Hodgkin's lymphoma in the elderly. <i>Drugs and Aging</i> , 2010 , 27, 211-38 | 4.7 | 7 |
| 8 | Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL. <i>Cytometry Part B - Clinical Cytometry</i> , 2010 , 78, 115-22 | 3.4 | 5 |
| 7 | Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009 , 1793, 971-8 | 4.9 | 54 |
| 6 | Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. <i>American Journal of Hematology</i> , 2009 , 84, 484-7 | 7.1 | 55 |
| 5 | Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2009 , 147, 89-96 | 4.5 | 21 |
| 4 | Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation. <i>Current Opinion in Oncology</i> , 2008 , 20, 502-8 | 4.2 | 9 |
| 3 | Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1940-9 | 1.9 | 17 |
| 2 | The role of bortezomib in the treatment of lymphoma. <i>Cancer Investigation</i> , 2007 , 25, 766-75 | 2.1 | 27 |
| 1 | Adenosine depresses transmitter release but is not the basis for tetanic fade at the neuromuscular junction of the rat. <i>Neuroscience Letters</i> , 1997 , 230, 81-4 | 3.3 | 13 |